The prognostic value of the ECG in hypertension: where are we now?

Area of Science:

• Cardiology
• Hypertension Research
• Diagnostic Imaging

Background:

• Left ventricular hypertrophy (LVH) in hypertensive patients significantly elevates cardiovascular morbidity and mortality risks.
• The electrocardiogram (ECG) is a primary diagnostic tool for LVH due to its accessibility and specificity, recommended in current hypertension guidelines.
• However, the ECG's diagnostic utility for LVH is constrained by its limited sensitivity.

Purpose of the Study:

• To critically evaluate the strengths and weaknesses of various ECG criteria used for diagnosing LVH.
• To review current data on the prognostic implications of ECG-diagnosed LVH, including gender-specific survival differences.
• To discuss the prognostic benefits of LVH regression and the role of integrating echocardiography with ECG for enhanced risk stratification in hypertension.

Main Methods:

• Review of existing literature on ECG criteria for LVH diagnosis.
• Analysis of recent clinical trial data, including the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
• Examination of studies comparing ECG and echocardiography for LVH detection and risk assessment.

Main Results:

• The review details the performance characteristics of common ECG criteria for LVH, highlighting limitations in sensitivity.
• Prognostic data indicates significant survival differences based on gender and the presence of LVH.
• Evidence suggests that regression of LVH confers prognostic benefits, as supported by trials like LIFE.

Conclusions:

• While ECG is a valuable tool for LVH diagnosis in hypertension, its poor sensitivity necessitates consideration of alternative or complementary methods.
• Combining ECG with echocardiography may offer improved risk stratification for hypertensive individuals.
• Further research into optimizing diagnostic strategies for LVH is crucial for managing cardiovascular risk in hypertension.